Liver Cancer Genomics - Cancer PHGKB -

Specific PHGKB|Cancer|PHGKB

Liver Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Mar 04, 2019

---

• Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.  
  Yoon Sarah et al. Oncogene 2018 37(32) 4443-4454
• Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).  
  Huemer Florian et al. BMC cancer 2018 18(1) 11
• Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma.  
  Li Binghua et al. Scientific reports 2017 7(1) 5517
• Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.  
  Dhanasekaran Renumathy et al. Gastroenterology 2019 156(2) 492-509
• Clinical significance of exosomal miRNAs and proteins in three human cancers with high mortality in China.  
  Li Li-Man et al. Oncology letters 2019 Jan 17(1) 11-22
• Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis.  
  Zhang Dongjing et al. The International journal of biological markers 2018 Aug 33(3) 266-274
• The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.  
  Serenari Matteo et al. Digestive surgery 2018 35(4) 303-310
• Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.  
  Deipolyi Amy R et al. Journal of vascular and interventional radiology : JVIR 2018 29(9) 1226-1235
• Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.  
  Jiang Peiyong et al. Proceedings of the National Academy of Sciences of the United States of America 2018 Oct
• Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study.  
  Nowak Albina et al. Medicine 2018 Oct 97(42) e12886
• Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.  
  Loaiza-Bonilla Arturo et al. Hepatic oncology 2015 Oct 2(4) 359-370
• The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.  
  Zou Shuang-Mei et al. Journal of cancer research and clinical oncology 2018 Aug
• Novel translational therapeutic strategy by sequencing primary liver cancer genomes.  
  Glantzounis Georgios K et al. Future oncology (London, England) 2017 13(12) 1049-1052
• Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas.  
  Song Yan-Zhou et al. World journal of gastroenterology 2018 Jul 24(28) 3145-3154
• Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.  
  Udar Nitin et al. Journal of cancer research and clinical oncology 2018 Jul